



PRESS RELEASE

Uppsala March 11, 2011

Delisting of Q-Med AB (publ)

NASDAQ OMX Stockholm has decided that Q-Med AB (publ) will be delisted from NASDAQ OMX Stockholm. The last trading day of the shares will be Friday, March 25, 2011.

As a consequence of the delisting of the share, Q-Med has decided not to announce the company's quarterly report for January – March 2011.

Uppsala March 11, 2011

The Board of Q-Med AB (publ)

Queries should be addressed to:

Carina Bolin, CEO & General Counsel

Telephone: +46 70 974 9117

Alexander Kotsinas, CFO

Telephone: +46 73 500 111

The information in this press release is such as that which Q-Med is required to disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for disclosure at 7.30 a.m. on March 11, 2011.

Q-Med AB is a medical device company that develops, manufactures, markets, and sells high quality medical implants for esthetic and medical use. The majority of the products are based on the company's patented technology, **NASHA™**, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane®** for filling lines and folds, contouring and creating volume in the face, **Macrolane™** for body contouring, **Durolane™** for the treatment of osteoarthritis of the hip and knee joints, **Deflux®** for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta®** for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med has about 650 coworkers, with almost 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail: info@q-med.com. Web: www.q-med.com